Advocacy Tools
Advocacy materials and tools developed by hepCoalition and partner organizations that can be adapted and used by advocates for local campaigns in their own contexts. Includes training materials, community monitoring/data collection, and graphics.
Materials in this section
Strengthening Advocacy for Hepatitis C Diagnostics: Malaysia Workshop Summary Report
Positive Malaysian Treatment Access and Advocacy Group, in partnership with FIND and TAG, convened the first advocacy workshop on hepatitis C diagnostics. More
Updated Training Manual for Treatment Advocates: Hepatitis C Virus & Coinfection with HIV
A Training Manual, developed by Treatment Action Group, supports community advocacy efforts for access to prevention, treatment, and care for HCV. More
Forging a Path to HCV Elimination: Simpler Tests and Affordable Generics
Report of the World Community Advisory Board on HCV Generics and Diagnostics, 18-20 July 2017, Bangkok, Thailand
Treatment activists met with generics and diagnostics companies to present demands and obtain strategic information from companies on critical access issues in low- and middle-income countries. More
Trainings
Hepatitis C and harm reduction for people who use drugs
In 2016, Médecins du Monde organized a series of trainings on hepatitis C intended for its Harm Reduction international teams and partners with a focus on people who use drugs. More
Dying at These Prices: Generic HCV Cure Denied
mapCrowd report #2
To mark World Hepatitis Day, Médecins du Monde and Treatment Action Group have produced a new report based on crowdsourced hepatitis C data from over 40 countries available at mapCrowd.org. More
Doctors of the World Opposes the Patent on Sofosbuvir
Hepatitis C: scourge, remedy and scandal
This is the first time in Europe that a medical NGO uses this juridical tool to improve patients access to treatment. More
mapCrowd
A new online crowdsourcing platform
mapCrowd, a new online crowdsourcing platform created by Médecins du Monde and Treatment Action Group, is designed to help collect and share up-to-date HCV information. More
Activist Strategies for Increasing Access to HCV Treatment in Low- and Middle-Income Countries
By Karyn Kaplan
A report, developed by TAG, presents a number of key strategies through real-world case studies and shows how HIV-targeted strategies can be adapted to increase HCV treatment access. More
Gilead’s License on Hepatitis C Drugs, Sofosbuvir and Ledipasvir: a Fool’s Bargain
Myths and facts
Gilead’s license is a fool’s bargain that inhibits access for nearly half the world’s HCV population. More
Minimum Costs to Produce Hepatitis C Direct-Acting Antivirals
by Andrew Hill, Bryony Simmons, Nikolien van de Van, Nathan Ford, Saye Khoo and Joe Fortunak
Minimum costs of treatment and diagnostics to cure hepatitis C were estimated at US$177-354 per person without genotyping, and US$267-444 per person with genotyping. More
